A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it
produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's
disease.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborators:
Seattle Institute for Biomedical and Clinical Research VA Puget Sound Health Care System